Navigation Links
Pitt team finds melatonin delays ALS symptom onset and death in mice

Melatonin injections delayed symptom onset and reduced mortality in a mouse model of the neurodegenerative condition amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to a new study by researchers at the University of Pittsburgh School of Medicine. In a report published online ahead of print in the journal Neurobiology of Disease, the team revealed that receptors for melatonin are found in the nerve cells, a finding that could launch novel therapeutic approaches.

Annually about 5,000 people are diagnosed with ALS, which is characterized by progressive muscle weakness and eventual death due to the failure of respiratory muscles, said senior investigator Robert Friedlander, M.D., UPMC Endowed Professor of neurosurgery and neurobiology and chair, Department of Neurological Surgery, Pitt School of Medicine. But the causes of the condition are not well understood, thwarting development of a cure or even effective treatments.

Melatonin is a naturally occurring hormone that is best known for its role in sleep regulation. After screening more than a thousand FDA-approved drugs several years ago, the research team determined that melatonin is a powerful antioxidant that blocks the release of enzymes that activate apoptosis, or programmed cell death.

"Our experiments show for the first time that a lack of melatonin and melatonin receptor 1, or MT1, is associated with the progression of ALS," Dr. Friedlander said. "We saw similar results in a Huntington's disease model in an earlier project, suggesting similar biochemical pathways are disrupted in these challenging neurologic diseases."

Hoping to stop neuron death in ALS just as they did in Huntington's, the research team treated mice bred to have an ALS-like disease with injections of melatonin or with a placebo. Compared to untreated animals, the melatonin group developed symptoms later, survived longer, and had less degeneration of motor neurons in the spinal cord.

"Much more work has to be done to unravel these mechanisms before human trials of melatonin or a drug akin to it can be conducted to determine its usefulness as an ALS treatment," Dr. Friedlander said. "I suspect that a combination of agents that act on these pathways will be needed to make headway with this devastating disease."


Contact: Anita Srikameswaran
University of Pittsburgh Schools of the Health Sciences

Related biology news :

1. Rescue me: New study finds animals do recover from neglect
2. Gene sequencing project finds new mutations to blame for a majority of brain tumor subtype
3. Exercise or make dinner? Study finds adults trade one healthy act for another
4. Sustainable fishing certification too lenient and discretionary, study finds
5. Couch potatoes may be genetically predisposed to being lazy, MU study finds
6. Notre Dame study finds Asian carp DNA not widespread in the Great Lakes
7. Marriage can threaten health: Study finds satisfied newlyweds more likely to gain weight
8. Southern California sagebrush better suited to climate change, UCI study finds
9. Pitt team finds immunity protein that ramps up inflammation, and agents that can block it
10. Study finds strong genetic component to childhood obesity
11. Do I know you? Memory patterns help us recall the social webs we weave, finds new Cornell study
Post Your Comments:
(Date:10/6/2015)... Oct. 6, 2015 Track Group, Inc. (OTCQX: ... it has signed a contract with the Virginia Department ... full range of sentences under the Department,s oversight. ... Americas. "This contract with the Virginia DOC will expand ... and advances our position as a trusted leader in ...
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 ... number of new SCIs estimated to reach 12,500 annually, ... Southern California Resource Services for Independent Living (SCRS-IL) ... in California opening doors to ... of programs and services, notably assistive technology services and ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... Florida , October 13, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, will be a featured presenting company at ... at the Wyndham Grand Hotel in Jupiter, ... TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company ...
(Date:10/13/2015)... ... 2015 , ... Clinovo recently appointed Jeff Parr and Ed Donaldson to its ... solutions business. , Jeff Parr has spent the past decade providing quality management software ... Fisher, and Ab Sciex to name a few. He is based in Salt ...
(Date:10/13/2015)... -- the United States , ... about 14% of all new cases of kidney cancer.   ... and Europe .  PRCC represents about ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that ... (publ) ("AstraZeneca") have completed enrolment in a global Phase II study ...
(Date:10/12/2015)... , Oct. 12, 2015 This report covers ... include cell type, products, applications, end-user markets and geographic ... HIGHLIGHTS The global cell expansion market generated revenue ... to reach revenues of $9.7 billion in 2015 and ... rate (CAGR) of 17.8% from 2015 to 2020. ...
Breaking Biology Technology: